TY - JOUR
T1 - How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review
AU - Takeuchi, Hiroyoshi
AU - Suzuki, Takefumi
AU - Uchida, Hiroyuki
AU - Kikuchi, Toshiaki
AU - Nakajima, Shinichiro
AU - Manki, Hiroshi
AU - Watanabe, Koichiro
AU - Kashima, Haruo
N1 - Funding Information:
Dr. Suzuki has received grants from the Japanese Society of Clinical Neuropsychopharmacology, Government of Canada Post-Doctoral Research Fellowships, Kanae Foundation, and Mochida Memorial Foundation within the past 5 years.
Funding Information:
Dr. Uchida has received grants from the Japanese Society of Clinical Neuropsychopharmacology, Japan Research Foundation for Clinical Pharmacology, Pfizer Health Research Foundation, and Mochida Memorial Foundation. Dr. Uchida has received speaker’s honoraria or manuscript fees from Dainippon Sumitomo Pharma, GlaxoSmithKlein, Janssen Pharmaceutical, and Otsuka Pharmaceutical within the past 5 years.
PY - 2011/8
Y1 - 2011/8
N2 - Objective: Antipsychotic dose reduction is generally recommended to occur after six months of clinical stabilization despite inadequate evidence. This timing issue was addressed in this study. Methods: This is an observational, retrospective and medical chart-based study. Inclusion criteria were (1) diagnosis of schizophrenia (DSM-IV), (2) being acutely psychotic at their first outpatient visit from May, 2002 to April, 2003, (3) having responded to antipsychotics and achieved clinical stabilization of acute symptoms, indexed as a fixation of regimen for four or more weeks, and (4) having one or more years of follow-up. Patients who had their antipsychotic doses reduced were then identified, and they were divided into two groups based on the waiting period before dose reduction: <24 weeks (Early Group) and ≥24 weeks (Standard Group). The rate of dose escalation for ≥20% during follow-up period was investigated as a proxy of clinical worsening. Results: After excluding stable patients at baseline, 211 patients met inclusion criteria. The mean ± SD waiting period before reducing antipsychotics was 122 ± 102 days. The rates of patients needing dose escalation were not significantly different between patients whose dose was reduced (N = 83) and those who was not (N = 128) (57.8% vs. 59.4%), and between Early Group (N = 59) and Standard Group (N = 24) (61.0% vs. 50.0%) although the reduction rate in antipsychotic dosage was significantly greater in Early Group (58.7% vs. 43.3%, p < 0.05). Conclusion: These findings may indicate that timeline until antipsychotic reduction in stable patients with schizophrenia could be earlier than recommended, although caution is needed in interpreting our retrospective results.
AB - Objective: Antipsychotic dose reduction is generally recommended to occur after six months of clinical stabilization despite inadequate evidence. This timing issue was addressed in this study. Methods: This is an observational, retrospective and medical chart-based study. Inclusion criteria were (1) diagnosis of schizophrenia (DSM-IV), (2) being acutely psychotic at their first outpatient visit from May, 2002 to April, 2003, (3) having responded to antipsychotics and achieved clinical stabilization of acute symptoms, indexed as a fixation of regimen for four or more weeks, and (4) having one or more years of follow-up. Patients who had their antipsychotic doses reduced were then identified, and they were divided into two groups based on the waiting period before dose reduction: <24 weeks (Early Group) and ≥24 weeks (Standard Group). The rate of dose escalation for ≥20% during follow-up period was investigated as a proxy of clinical worsening. Results: After excluding stable patients at baseline, 211 patients met inclusion criteria. The mean ± SD waiting period before reducing antipsychotics was 122 ± 102 days. The rates of patients needing dose escalation were not significantly different between patients whose dose was reduced (N = 83) and those who was not (N = 128) (57.8% vs. 59.4%), and between Early Group (N = 59) and Standard Group (N = 24) (61.0% vs. 50.0%) although the reduction rate in antipsychotic dosage was significantly greater in Early Group (58.7% vs. 43.3%, p < 0.05). Conclusion: These findings may indicate that timeline until antipsychotic reduction in stable patients with schizophrenia could be earlier than recommended, although caution is needed in interpreting our retrospective results.
KW - Antipsychotics
KW - Dose reduction
KW - Schizophrenia
KW - Timing
KW - Waiting period
UR - http://www.scopus.com/inward/record.url?scp=79960578098&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960578098&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychires.2011.01.007
DO - 10.1016/j.jpsychires.2011.01.007
M3 - Article
C2 - 21303712
AN - SCOPUS:79960578098
SN - 0022-3956
VL - 45
SP - 1083
EP - 1088
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
IS - 8
ER -